These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8294050)

  • 1. DNA-topoisomerase I and II: biologic features and their role in drug resistance.
    Russo D; Marie JP; Delmer A; Zhou D; Suberville AM; Baccarani M; Zittoun R
    Haematologica; 1993; 78(4):201-7. PubMed ID: 8294050
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Beck WT; Danks MK
    Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].
    Ishida R; Andoh T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):952-61. PubMed ID: 8002633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inhibitors of DNA topoisomerases].
    Andoh T
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance.
    Liu LF; D'Arpa P
    Important Adv Oncol; 1992; ():79-89. PubMed ID: 1316311
    [No Abstract]   [Full Text] [Related]  

  • 6. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line.
    Pu QQ; Bezwoda WR
    Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
    Valkov NI; Sullivan DM
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA topoisomerases and topoisomerase inhibitors.
    Giaccone G
    Pathol Biol (Paris); 1994 Apr; 42(4):346-52. PubMed ID: 7808789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I.
    Snapka RM; Gao H; Grabowski DR; Brill D; Chan KK; Li L; Li GC; Ganapathi R
    Biochem Biophys Res Commun; 2001 Feb; 280(4):1155-60. PubMed ID: 11162648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy.
    Smith PJ
    Bioessays; 1990 Apr; 12(4):167-72. PubMed ID: 2159289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects.
    Boege F
    Eur J Clin Chem Clin Biochem; 1996 Nov; 34(11):873-88. PubMed ID: 8960461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the anticancer drug oracin on mouse liver topoisomerases I and II.
    Stuchlík S; Turna J; Miko M
    J Pharm Pharmacol; 2005 May; 57(5):657-9. PubMed ID: 15901355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.
    Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C
    Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I.
    Hoernlein RF; Orlikowsky T; Zehrer C; Niethammer D; Sailer ER; Simmet T; Dannecker GE; Ammon HP
    J Pharmacol Exp Ther; 1999 Feb; 288(2):613-9. PubMed ID: 9918566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
    Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
    Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
    Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
    J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase II expression in normal haemopoietic cells and chronic lymphocytic leukaemia: drug sensitivity or resistance?
    McKenna SL; Whittaker JA; Padua RA; Holmes JA
    Leukemia; 1993 Aug; 7(8):1199-203. PubMed ID: 8394482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA topoisomerase II poisons and inhibitors.
    Capranico G; Giaccone G; D'Incalci M
    Cancer Chemother Biol Response Modif; 1999; 18():125-43. PubMed ID: 10800480
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.